Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia

Schizophrenia Research

Volumn 32, Issue 2, 1998, Pages 101-106

  Kapitany, T ^a,b   Meszaros, K ^a   Lenzinger, E ^a   Schindler, S D ^a   Barnas, C ^a   Fuchs, K ^a   Sieghart, W ^a   Aschauer, H N ^a   Kasper, S ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CYP2D6; Genetic polymorphism; Genotyping; Neuroleptic drug metabolism; Schizophrenia; Tardive dyskinesia

Indexed keywords

DEBRISOQUINE; SPARTEINE;

ADULT; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; DNA POLYMORPHISM; DRUG METABOLISM; FEMALE; GENE MUTATION; GENOTYPE; HETEROZYGOSITY; HUMAN; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DYSKINESIA, DRUG-INDUCED; FEMALE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, GENETIC; SCHIZOPHRENIA;

EID: 0032572604     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(98)00038-3     Document Type: Article

References (28)

1. Andreassen, O.A., MacEwan, T., Gulbrandsen, A.K., McCreadie, R.G., Steen, V.M., 1997. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacol. Berl. 131, 174-179.
2. Armstrong, M., Daly, A.K., Blennerhasset, R., Ferrier, N., Idle, J.R., 1997. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br. J. Psychiatry 170, 23-26.
3. Arthur, H., Dahl, M.L., Siwers, B., Sjöqvist, F., 1995. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J. Clin. Psychopharmacol. 15, 211-216.
4. Brosen, K., 1993. Isozyme specific drug oxidation: genetic polymorphism and drug-drug interactions. Nord. J. Psychiatry 47 (Suppl. 30), 21-26.
5. Dahl, M.L., Johansson, I., Palmertz, M.P., Ingelman Sundberg, M., Sjöqvist, F., 1992. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population. Clin. Pharmacol. Ther. 51, 12-17.
6. Daly, K.A., Steward, A., 1995. Use of the expand long template PCR system in genotyping for polymorphisms in the human cytochrome P450 CYP2D6 gene. Biochemica 4, 31-32.
7. Daniels, J., Williams, J., Asherson, P., McGuffin, P., Owen, M., 1995. No association between schizophrenia and polymorphisms within the genes for debrisoquine 4-hydroxylase (CYP2D6) and the dopamine transporter (DAT). Am. J. Med. Genet. 60, 85-87.
8. Dawson, E., Powell, J.F., Nöthen, M.M., Crocq, M.A., Lanczik, M., Körner, J., Rietschel, M., van Os, J., Wright, P., Gill, M., 1994. An association study of debrisoquine hydroxylase (CYP2D6) polymorphisms in schizophrenia. Psychiatric Genet. 4, 215-218.
9. Fairbairn, A.F., Rowell, F.J., Hui, S.M., Hassanyeh, F., Robinson, A.J., Eccleston, D., 1983. Serum concentration of depot neuroleptics in tardive dyskinesia. Br. J. Psychiatry 142, 579-583.
10. Glazer, W.M., Morgenstern, H., Doucette, J.T., 1993. The prediction of chronic persistent versus intermittent tardive dyskinesia: a retrospective predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medication. J. Clin. Psychiatry 54, 133-139.
11. Heim, M., Meyer, U.A., 1990. Genotyping of poor metaboliser of debrisoquine by allele-specific PCR amplification. Lancet 336, 529-532.
12. Iwahashi, K., 1994. CYP2D6 genotype and possible susceptibility to the neuroleptic malignant syndrome. Biol. Psychiatry 36, 780-782.
13. Jeste, D.V., DeLisi, L.E., Zalcman, S., Wise, C.D., Phelps, B.H., Rosenblatt, J.E., Potkin, S.G., Bridge, T.P., Wyatt, R.J., 1981. A biochemical study of tardive dyskinesia in young male patients. Psychiatry Res. 4, 327-331.
14. Jeste, D.V., Linnoila, M., Wagner, R.L., Wyatt, R.J., 1982. Serum neuroleptic concentrations and tardive dyskinesia. Psychopharmacol. Berl. 76, 377-380.
15. Kane, J.M., Rifkin, A., Woerner, M., Reardon, G., Sarantakos, S., Schiebel, D., Ramos-Lorenzi, J., 1983. Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. Arch. Gen. Psychiatry 40, 893-896.
16. Kane, J.M., Woerner, M., Borenstein, M., Wegner, J., Lieberman, J., 1986. Inegrating incidence and prevalence of tardive dyskinesia. Psychopharmacol. Bull. 22, 254-258.
17. Maghoub, A., Idle, J.R., Dring, L.G., Lancaster, R., Smith, R.L., 1977. Polymorphic hydroxylation of debrisoquine in man. Lancet 2, 584-586.
18. Mannens, G., Huang, M.L., Meuldermans, W., Hedrickx, J., Woestenborghs, R., Heykants, J., 1993. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab. Dispos. Biol. Fate Chem. 21, 1134-1141.
19. Miller, C.H., Simioni, I., Oberbauer, H., Schwitzer, J., Barnas, C., Kulhanek, F., Boissel, K.E., Meise, U., Hinterhuber, H., Fleischhacker, W.W., 1995. Tardive dyskinesia prevalence rates during a ten-year follow-up. J. Nerv. Mental Dis. 183, 404-407.
20. Nakamura, K., Goto, F., Ray, W.A., McAllister, C.B., Jacqz, E., Wilkinson, G.R., Branch, R.A., 1985. Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian population. Clin. Pharmacol. Ther. 38, 402-408.
21. Rudorfer, M.V., 1983. Pharmacokinetics of psychotropic drugs in special populations. J. Clin. Psychiatry 54 (Suppl. 9), 50-54.
22. Sachse, C., Brockmöller, J., Bauer, S., Roots, I., 1997. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am. J. Hum. Genet. 60, 284-295.
23. Schooler, N.R., Kane, J.M., 1982. Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry 39, 486-487.
24. Simpson, G.M., Lee, J.H., Zoubok, B., Gardos, G., 1979. A rating scale for tardive dyskinesia. Psychopharmacology 64, 171-179.
25. Spina, E., Ancione, M., DiRosa, A.E., Meduri, M., Caputi, A.P., 1992. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur. J. Clin. Pharmacol. 42, 347-348.
26. Vallada, H., Collier, D., Dawson, E., Owen, M., Nanko, S., Murray, R., Gill, M., 1992. Debrisoquine 4-hydroxylase (CYP2D6) locus and possible susceptibility to schizophrenia. Lancet 340, 181-182.
27. Vinks, A., Inaba, T., Otton, S.V., Kalow, W., 1982. Spartein metabolism in Canadian Caucasians. Clin. Pharmacol. Ther. 31, 23-29.
28. Yesavage, J.A., Tanke, E.D., Sheikh, J.I., 1987. Tardive dyskinesia and steady-state serum levels of thiothixene. Arch. Gen. Psychiatry 44, 913-915.